These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18359336)

  • 1. Merck's Careful Study of Vioxx.
    Mayer TV
    Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse cardiovascular effects of rofecoxib.
    Furberg CD
    N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
    [No Abstract]   [Full Text] [Related]  

  • 4. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse cardiovascular effects of rofecoxib.
    Nissen SE
    N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
    [No Abstract]   [Full Text] [Related]  

  • 6. The Vioxx® legacy: Enduring lessons from the not so distant past.
    McIntyre WF; Evans G
    Cardiol J; 2014; 21(2):203-5. PubMed ID: 24752949
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac risks with COX-2 inhibitors.
    Ashworth AJ
    CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
    [No Abstract]   [Full Text] [Related]  

  • 8. What have we learnt from Vioxx?
    Krumholz HM; Ross JS; Presler AH; Egilman DS
    BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 10. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 11. [How many harmed by rofecoxib in Germany?].
    Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
    Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to the Vioxx debacle.
    Knudsen JF; Sokol GH
    Am J Med; 2006 Jan; 119(1):93-4. PubMed ID: 16431207
    [No Abstract]   [Full Text] [Related]  

  • 13. The Vioxx debacle revisited.
    Daikh DI
    Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2 selective inhibitors and heart health.
    Simon LS; White WB
    Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 16. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 17. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 18. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
    Jerie P
    Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
    [No Abstract]   [Full Text] [Related]  

  • 19. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 20. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.